k_老虎社区_美港股上老虎

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":690174218,"tweetId":"690174218","gmtCreate":1639650823884,"gmtModify":1639650823884,"author":{"id":3581746780935690,"idStr":"3581746780935690","authorId":3581746780935690,"authorIdStr":"3581746780935690","name":"qstocks","avatar":"https://static.tigerbbs.com/cd471dd6c55721dad90e1c808f35bdd8","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":0,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>k</body></html>","htmlText":"<html><head></head><body>k</body></html>","text":"k","highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/690174218","repostId":1171817404,"repostType":4,"repost":{"id":"1171817404","kind":"news","pubTimestamp":1639648605,"share":"https://www.laohu8.com/m/news/1171817404?lang=&edition=full","pubTime":"2021-12-16 17:56","market":"us","language":"en","title":"46 Biggest Movers From Yesterday","url":"https://stock-news.laohu8.com/highlight/detail?id=1171817404","media":"Benzinga","summary":"Gainers\n\nTheseus Pharmaceuticals, Inc. gained 34.1% to settle at $12.58 on Wednesday.\nCMC Materials,","content":"Gainers\n<ul>\n <li>Theseus Pharmaceuticals, Inc.&nbsp;gained 34.1% to settle at $12.58 on Wednesday.</li>\n <li>CMC Materials, Inc.&nbsp;climbed 33.9% to close at $195.50 on Wednesday after the company announced it will be acquired by Entegris for $6.5 billion in cash and stock.</li>\n <li>Biofrontera Inc.&nbsp;shares jumped 26.4% to settle at $6.95 on Wednesday after Benchmark initiated coverage on the stock with a Buy rating and announced a $11 price target.</li>\n <li>Regional Health Properties, Inc.&nbsp;gained 23.8% to close at $6.70.Regional Health Props, last month, posted a Q3 loss of $1.25 per share.</li>\n <li>Gemini Therapeutics, Inc.&nbsp;rose 23.1% to settle at $2.99 after HC Wainwright &amp; Co initiated coverage on the stock with a Buy rating and a $20 price target.</li>\n <li>CN Energy Group. Inc.&nbsp;jumped 22.4% to close at $3.01.</li>\n <li>Mesoblast Limited&nbsp;climbed 19.2% to settle at $4.97. Mesoblast shares dropped around 28% on Tuesday after the company was notified by Novartis that it has chosen to terminate the agreement with Mesoblast prior to closing.</li>\n <li>Broadstone Acquisition Corp.&nbsp;gained 19.1% to close at $10.68.</li>\n <li>Cabaletta Bio, Inc.&nbsp;jumped 18.2% to settle at $3.97.</li>\n <li>Ensysce Biosciences, Inc.&nbsp;surged 17.4% to close at $4.11. Ensysce Biosciences said that the first patients have been enrolled in Phase 1 study of PF614-MPAR, its unique technology platform to provide opioid overdose protection.</li>\n <li>Trio-Tech International&nbsp;gained 16.6% to close at $9.42.</li>\n <li>Aerovate Therapeutics, Inc.&nbsp;jumped 16.3% to close at $12.34 after the company announced the initiation of its IMPAHCT Phase 2b/Phase 3 trial of AV-101 In Pulmonary Arterial Hypertension.</li>\n <li>Optical Cable Corporation&nbsp;gained 16.2% to settle at $6.40.</li>\n <li>Conn's, Inc.&nbsp;rose 16.1% to close at $20.81. Conn's Board of Directors authorized a repurchase program of $150 million of its outstanding stock.</li>\n <li>Design Therapeutics, Inc.&nbsp;surged 16% to settle at $20.36.</li>\n <li>Bird Global, Inc.&nbsp;gained 15.7% to close at $8.97.</li>\n <li>VerifyMe, Inc.&nbsp;jumped 13.7% to close at $3.65.</li>\n <li>East Stone Acquisition Corporation&nbsp;gained 12.9% to close at $15.24 after declining 26% on Tuesday.</li>\n <li>Vir Biotechnology, Inc.&nbsp;gained 12.1% to close at $51.62 after the company announced new preclinical data demonstrating the impact of the significant antigenic shift of the new SARS-CoV-2 Omicron variant.</li>\n <li>SeaChange International, Inc.&nbsp;rose 11.9% to close at $1.69 after the company reported better-than-expected Q3 results.</li>\n <li>Nxt-ID, Inc.&nbsp;shares rose 11.7% to close at $2.78 after the company said it was awarded U.S. General Services Administration contract to distribute personal emergency response systems to Federal, State and Local government purchasers.</li>\n <li>Tandem Diabetes Care, Inc.&nbsp;climbed 10.5% to close at $144.34.</li>\n <li>Eli Lilly and Company&nbsp;climbed 10.4% to close at $275.28 after the company issued FY21 EPS guidance above analyst estimates.</li>\n <li>Borr Drilling Limited&nbsp;gained 9.2% to close at $1.67 after declining over 4% on Tuesday..</li>\n <li>Galera Therapeutics, Inc.&nbsp;gained 7.4% to close at $2.90 after BTIG upgraded the stock from Neutral to Buy and announced a $15 price target. Galera Therapeutics shares jumped around 96% on Tuesday after the company announced the primary endpoint met statistical significance in corrected topline efficacy data of Phase 3 ROMAN trial of avasopasem.</li>\n</ul>\nLosers\n<ul>\n <li>Atai Life Sciences N.V.&nbsp;dropped 31.9% to close at $6.82 on Wednesday.</li>\n <li>China Xiangtai Food Co., Ltd.&nbsp;fell 28.2% to settle at $1.81. The company earlier announced the completion of its first purchase of spot Bitcoin miners worth $7 million.</li>\n <li>Aspen Group, Inc.&nbsp;shares declined 27.2% to close at $1.90 on Wednesday after the company reported worse-than-expected Q2 results and cut FY22 guidance.</li>\n <li>REV Group, Inc.&nbsp;fell 25.5% to close at $11.87 after the company reported worse-than-expected Q4 EPS and sales results and issued FY22 sales guidance below estimates.</li>\n <li>Idera Pharmaceuticals, Inc.&nbsp;shares dipped 25.3% to close at $0.6501 on Wednesday after the company announced tilsotolimod updates. The company said no further enrollment in ILLUMINATE-206 trial is planned at this point.</li>\n <li>LianBio&nbsp;fell 21.3% to close at $7.68. LianBio reported a Q3 loss of $0.63 per share.</li>\n <li>The Oncology Institute, Inc.&nbsp;fell 17.9% to close at $6.25.</li>\n <li>Alzamend Neuro, Inc.&nbsp;fell 15.9% to close at $2.59 after jumping 28% on Tuesday.</li>\n <li>LogicBio Therapeutics, Inc&nbsp;dropped 15.5% to close at $2.45. Barclays maintained LogicBio Therapeutics with an Overweight and lowered the price target from $24 to $8.</li>\n <li>Legend Biotech Corporation&nbsp;shares fell 15.3% to close at $41.14 after the company reported an offering of $300 million in ADSs.</li>\n <li>Huadi International Group Co., Ltd.&nbsp;fell 15% to close at $27.62.</li>\n <li>iSpecimen Inc.&nbsp;fell 13.3% to close at $10.87.</li>\n <li>MIND Technology, Inc.&nbsp;shares fell 12.9% to close at $1.55. MIND Technology shares gained 30% on Tuesday after the company reported it entered into a Cooperative Research and Development Agreement with the United States Navy's Naval Surface Warfare Center, Panama City Division.</li>\n <li>Adagio Therapeutics, Inc.&nbsp;fell 12.5% to close at $6.35 after Stifel downgraded the stock from Buy to Hold and lowered the price target from $50 to $9. Adagio Therapeutics shares dipped 79% on Tuesday after the company said based on the in vitro findings related to Omicron, it plans to pause patient recruitment in its Phase 2/3 COVID-19 treatment trial at clinical sites in South Africa.</li>\n <li>Zai Lab Limited&nbsp;fell 12.4% to close at $54.90.</li>\n <li>Cerence Inc.&nbsp;dropped 11.4% to close at $69.20. Cerence’s board promoted Dr. Stefan Ortmanns to Chief Executive Officer and Director.</li>\n <li>ABM Industries Incorporated&nbsp;fell 11% to close at $40.88 as the company reported fourth-quarter revenue growth of 14.2% year-over-year to $1.69 billion, comprised of 7.4% organic growth and 6.8% from acquisition.</li>\n <li>BeiGene, Ltd.&nbsp;fell 10.7% to close at $248.56. BeiGene reported authorisation of BRUKINSA (zanubrutinib) from the UK’s MHRA for the treatment of adults with Waldenström’s Macroglobulinemia in Great Britain.</li>\n <li>Cooper-Standard Holdings Inc.&nbsp;fell 7.1% to close at $19.71.</li>\n <li>Nisun International Enterprise Development Group Co., Ltd&nbsp;fell 6.9% to close at $3.50.</li>\n <li>I-Mab&nbsp;fell 5% to close at $46.97. I-Mab received IND approval for Phase 1 clinical trial of bispecific antibody TJ-CD4B in solid tumors in China.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>46 Biggest Movers From Yesterday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n46 Biggest Movers From Yesterday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-16 17:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/21/12/24638543/46-biggest-movers-from-yesterday>Benzinga</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nGainers\n\nTheseus Pharmaceuticals, Inc. gained 34.1% to settle at $12.58 on Wednesday.\nCMC Materials, Inc. climbed 33.9% to close at $195.50 on Wednesday after the company announced it will be acquired...\n\n<a href=\"https://www.benzinga.com/news/21/12/24638543/46-biggest-movers-from-yesterday\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VIR":"Vir Biotechnology, Inc.","BGNE":"百济神州"},"source_url":"https://www.benzinga.com/news/21/12/24638543/46-biggest-movers-from-yesterday","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1171817404","content_text":"Gainers\n\nTheseus Pharmaceuticals, Inc. gained 34.1% to settle at $12.58 on Wednesday.\nCMC Materials, Inc. climbed 33.9% to close at $195.50 on Wednesday after the company announced it will be acquired by Entegris for $6.5 billion in cash and stock.\nBiofrontera Inc. shares jumped 26.4% to settle at $6.95 on Wednesday after Benchmark initiated coverage on the stock with a Buy rating and announced a $11 price target.\nRegional Health Properties, Inc. gained 23.8% to close at $6.70.Regional Health Props, last month, posted a Q3 loss of $1.25 per share.\nGemini Therapeutics, Inc. rose 23.1% to settle at $2.99 after HC Wainwright & Co initiated coverage on the stock with a Buy rating and a $20 price target.\nCN Energy Group. Inc. jumped 22.4% to close at $3.01.\nMesoblast Limited climbed 19.2% to settle at $4.97. Mesoblast shares dropped around 28% on Tuesday after the company was notified by Novartis that it has chosen to terminate the agreement with Mesoblast prior to closing.\nBroadstone Acquisition Corp. gained 19.1% to close at $10.68.\nCabaletta Bio, Inc. jumped 18.2% to settle at $3.97.\nEnsysce Biosciences, Inc. surged 17.4% to close at $4.11. Ensysce Biosciences said that the first patients have been enrolled in Phase 1 study of PF614-MPAR, its unique technology platform to provide opioid overdose protection.\nTrio-Tech International gained 16.6% to close at $9.42.\nAerovate Therapeutics, Inc. jumped 16.3% to close at $12.34 after the company announced the initiation of its IMPAHCT Phase 2b/Phase 3 trial of AV-101 In Pulmonary Arterial Hypertension.\nOptical Cable Corporation gained 16.2% to settle at $6.40.\nConn's, Inc. rose 16.1% to close at $20.81. Conn's Board of Directors authorized a repurchase program of $150 million of its outstanding stock.\nDesign Therapeutics, Inc. surged 16% to settle at $20.36.\nBird Global, Inc. gained 15.7% to close at $8.97.\nVerifyMe, Inc. jumped 13.7% to close at $3.65.\nEast Stone Acquisition Corporation gained 12.9% to close at $15.24 after declining 26% on Tuesday.\nVir Biotechnology, Inc. gained 12.1% to close at $51.62 after the company announced new preclinical data demonstrating the impact of the significant antigenic shift of the new SARS-CoV-2 Omicron variant.\nSeaChange International, Inc. rose 11.9% to close at $1.69 after the company reported better-than-expected Q3 results.\nNxt-ID, Inc. shares rose 11.7% to close at $2.78 after the company said it was awarded U.S. General Services Administration contract to distribute personal emergency response systems to Federal, State and Local government purchasers.\nTandem Diabetes Care, Inc. climbed 10.5% to close at $144.34.\nEli Lilly and Company climbed 10.4% to close at $275.28 after the company issued FY21 EPS guidance above analyst estimates.\nBorr Drilling Limited gained 9.2% to close at $1.67 after declining over 4% on Tuesday..\nGalera Therapeutics, Inc. gained 7.4% to close at $2.90 after BTIG upgraded the stock from Neutral to Buy and announced a $15 price target. Galera Therapeutics shares jumped around 96% on Tuesday after the company announced the primary endpoint met statistical significance in corrected topline efficacy data of Phase 3 ROMAN trial of avasopasem.\n\nLosers\n\nAtai Life Sciences N.V. dropped 31.9% to close at $6.82 on Wednesday.\nChina Xiangtai Food Co., Ltd. fell 28.2% to settle at $1.81. The company earlier announced the completion of its first purchase of spot Bitcoin miners worth $7 million.\nAspen Group, Inc. shares declined 27.2% to close at $1.90 on Wednesday after the company reported worse-than-expected Q2 results and cut FY22 guidance.\nREV Group, Inc. fell 25.5% to close at $11.87 after the company reported worse-than-expected Q4 EPS and sales results and issued FY22 sales guidance below estimates.\nIdera Pharmaceuticals, Inc. shares dipped 25.3% to close at $0.6501 on Wednesday after the company announced tilsotolimod updates. The company said no further enrollment in ILLUMINATE-206 trial is planned at this point.\nLianBio fell 21.3% to close at $7.68. LianBio reported a Q3 loss of $0.63 per share.\nThe Oncology Institute, Inc. fell 17.9% to close at $6.25.\nAlzamend Neuro, Inc. fell 15.9% to close at $2.59 after jumping 28% on Tuesday.\nLogicBio Therapeutics, Inc dropped 15.5% to close at $2.45. Barclays maintained LogicBio Therapeutics with an Overweight and lowered the price target from $24 to $8.\nLegend Biotech Corporation shares fell 15.3% to close at $41.14 after the company reported an offering of $300 million in ADSs.\nHuadi International Group Co., Ltd. fell 15% to close at $27.62.\niSpecimen Inc. fell 13.3% to close at $10.87.\nMIND Technology, Inc. shares fell 12.9% to close at $1.55. MIND Technology shares gained 30% on Tuesday after the company reported it entered into a Cooperative Research and Development Agreement with the United States Navy's Naval Surface Warfare Center, Panama City Division.\nAdagio Therapeutics, Inc. fell 12.5% to close at $6.35 after Stifel downgraded the stock from Buy to Hold and lowered the price target from $50 to $9. Adagio Therapeutics shares dipped 79% on Tuesday after the company said based on the in vitro findings related to Omicron, it plans to pause patient recruitment in its Phase 2/3 COVID-19 treatment trial at clinical sites in South Africa.\nZai Lab Limited fell 12.4% to close at $54.90.\nCerence Inc. dropped 11.4% to close at $69.20. Cerence’s board promoted Dr. Stefan Ortmanns to Chief Executive Officer and Director.\nABM Industries Incorporated fell 11% to close at $40.88 as the company reported fourth-quarter revenue growth of 14.2% year-over-year to $1.69 billion, comprised of 7.4% organic growth and 6.8% from acquisition.\nBeiGene, Ltd. fell 10.7% to close at $248.56. BeiGene reported authorisation of BRUKINSA (zanubrutinib) from the UK’s MHRA for the treatment of adults with Waldenström’s Macroglobulinemia in Great Britain.\nCooper-Standard Holdings Inc. fell 7.1% to close at $19.71.\nNisun International Enterprise Development Group Co., Ltd fell 6.9% to close at $3.50.\nI-Mab fell 5% to close at $46.97. I-Mab received IND approval for Phase 1 clinical trial of bispecific antibody TJ-CD4B in solid tumors in China.","news_type":1},"isVote":1,"tweetType":1,"viewCount":928,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":1,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/690174218"}